🇺🇸

US SEC Filing Intelligence

· daily

US Executive Compensation Proxy SEC Filings — March 12, 2026

Across 40 DEF 14A proxy filings, a dominant theme is robust 2025 performance justifying executive compensation, with 18 companies (45%) reporting positive YoY revenue/FFO growth (e.g., GE Aerospace +18% revenue to $45.9B, Healthpeak 4% NOI growth), strong capital returns via dividends/buybacks exceeding $2B aggregate (e.g., Avery Dennison $572M repurchases, First Hawaiian $100M repurchases + $250M new program), and high occupancy/dividend yields in REITs (Getty 99.7% occupancy, 3.2% dividend hike). Banks and utilities show resilience with NII growth (First Hawaiian +6.5%) and operational awards (PSEG #1 J.D. Power), while 10 filings (25%) flag mixed sentiment from sales softness (Avery low-single digit label growth) or net losses (Metallus -$1.2M). Board refreshes are prevalent (15+ companies adding/retiring directors), with near-universal say-on-pay and auditor ratification proposals ahead of April-May 2026 meetings. Insider pledges in banks (Citizens 5 execs pledging shares) signal caution, but no widespread selling; pending M&A like NorthWestern-Black Hills adds accretion potential. Portfolio implication: overweight resilient REITs/banks with strong returns, monitor industrials/pharma for tariff/decline impacts.

40 high priority 40 total filings
· daily

US Executive Officer Management Changes SEC — March 12, 2026

Across 39 filings in the USA Executive & Director Changes stream (Mar 12, 2026), a dominant theme is planned CEO and executive successions/transitions in 12 companies (e.g., Build-A-Bear, Blue Ridge Bankshares, Karman Holdings, Angi, Halozyme), often framed positively amid growth or turnarounds, contrasting with abrupt resignations citing concerns in Vestand (2 directors). Board appointments dominate positively (14 instances, e.g., iRhythm, Quest Diagnostics, Colgate-Palmolive) adding healthcare/tech expertise, while retirements are routine (e.g., Arthur J. Gallagher, Matson). Period trends show outliers like TIC Solutions' 39% YoY revenue growth to $1.53B and Adobe's 12% YoY to $6.40B Q1 FY2026, but net losses persist (TIC $87.1M FY2025); equity plan expansions (Enanta +1.6M shares, Analog 95% approval) signal talent retention. Mixed sentiment overall (positive 14, neutral 15, negative/mixed 10), with high materiality CEO/CFO shifts (avg 8/10) implying leadership stability as a portfolio bullish amid M&A/integration (Axcelis-Veeco). Implications: Favor companies with internal/promoted successors and revenue momentum for near-term alpha; monitor banks/tech for transition risks.

39 high priority 39 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — March 12, 2026

Across 50 filings in the USA Corporate Distress & Bankruptcy stream, overarching themes reveal acute liquidity pressures driving 28+ capital raises/debt refinancings (e.g., $30M Longeveron private placement, $673M Dianthus equity), 12 credit amendments/waivers signaling covenant strain (XBP eliminating min availability, NGL ABL cut to $425M), and 5 delisting/reverse split risks (Cryo-Cell NYSE warning, Allurion to OTC, CXApp extension to Sep 2026). Period-over-period data sparse but highlights distress: Universal Electronics FY2025 sales -7% YoY to $368M, Q4 -21% to $87M despite margin expansion to 29.7% and op cash $23.6M; no broad YoY revenue growth, with declines/outliers in sales volumes/cash burn implied across microcaps. Insider activity minimal, but board changes (Turtle Beach activist settlement, Beneficient Hicks appt) suggest governance shifts amid distress. Forward-looking catalysts cluster in Q2-Q4 2026: trial readouts (Longeveron 3Q26), mergers (NIMU Jun30), note redemptions (Chemours 2027 notes). Portfolio implications: broad small/midcap distress via dilutive equity (NIMU 95.5% dilution, ECD 207M shares), higher-cost debt (Chemours 7.875% vs prior 5.75%), but successful raises extend runways (Firefly to 2027 lockups); short high-dilution names, buy post-stabilization refinancings.

50 high priority 50 total filings
· daily

US SEC Trading Suspension Halt Orders — March 12, 2026

Four small-cap companies across biotech, medtech, and tech sectors reported critical listing compliance issues on NYSE American and Nasdaq, highlighting widespread pressure from low bid prices and market caps as of March 2026. Overarching themes include delisting risks (3/4 filings), with one full regain (ATPC), one extension (CXApp), one appeal to OTC (Allurion), and one pending plan (CCEL); no direct financial period-over-period trends available, but compliance periods show deteriorating bid prices YoY (e.g., ATPC at $0.10 in Jan 2026 after prior notices). Critical developments: Nasdaq extensions averaging 180 days signal temporary relief, but NYSE actions faster to suspension; market implications include heightened volatility, OTC liquidity risks, and reverse split catalysts. Portfolio-level patterns: 75% Nasdaq-focused with $1 bid failures over 30+ days, mixed sentiments (2/4), high materiality (avg 8.75/10), pointing to small-cap distress but turnaround potential via FDA/operational plans. No insider trading or capital allocation shifts noted across filings, emphasizing regulatory as primary driver.

4 high priority 4 total filings
· daily

US Corporate Board Director Changes SEC Filings — March 12, 2026

Across 39 SEC filings on USA Board Room Changes (Mar 12, 2026), overarching themes include 18 positive executive/board appointments/resuccessions (e.g., healthcare/tech leaders like Quest Diagnostics adding ex-Walgreens CEO, iRhythm adding UnitedHealth exec), 12 neutral retirements/planned transitions, and 4 negative resignations (e.g., Vestand citing compliance concerns amid ops closures), signaling net board strengthening amid growth strategies. Period-over-period trends show revenue acceleration in outliers like TIC Solutions (+39% FY25 rev YoY to $1.53B, +94% Q4), Adobe (+12% Q1 FY26 rev to $6.40B, subscription +13%), and Build-A-Bear (5th record FY25 at $529.8M), contrasting net losses (TIC -$87.1M improved 28% YoY). Annual meetings largely passed director elections/equity plans (Enanta, Analog Devices, Sanmina, Next Tech >93% support). Critical developments: 7 CEO/CFO transitions (planned successions bullish, sudden departures risky), equity plan expansions (Enanta +1.6M shares despite 22% opposition), debt reductions (B Riley -$37.9M). Portfolio-level: Healthcare (9/39) shows strongest refresh (+ experts from BMS, Tenet, Walgreens), tech/defense maturing via successions; implications favor long-term stability but watch ops risks in consumer/financials.

39 high priority 39 total filings
· daily

US Merger & Acquisition SEC Filings — March 12, 2026

A surge in US M&A and takeover activity dominates the 10 filings, with 7 announcing or completing strategic acquisitions, SPAC business combinations, or asset sales, reflecting strong deal momentum amid positive sentiment in 8/10 cases. SPACs like Inflection Point IV, Plum IV, and Quetta show advanced progress toward closings via shareholder approvals and support agreements, while traditional M&A includes Laird Superfood's $38.5M Navitas buy and T Stamp's dual cyber deals. No aggregate period-over-period financial trends available across filings due to event-driven nature, but transaction volumes highlight scaling ambitions in nutrition, AI/cybersecurity, and energy. Risks limited to Oak Woods' Nasdaq delisting threat and Ribbon's repeated EGM adjournments signaling proxy hurdles. Portfolio-level pattern: 6/10 filings involve tech/AI/energy targets, implying sector consolidation; actionable now as approvals cluster in March 2026 with Q3 closings ahead.

10 high priority 10 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 12, 2026

Overnight SEC filings reveal mixed FY2025 results across sectors, with financial institutions like Citizens Financial Services (NII +13.3% YoY, NIM to 3.50%) and Velocity Financial (loans +28% YoY, NI +53%) showing robust growth amid NIM expansion, while consumer-facing firms like Vivid Seats (GOV -31% YoY), Sleep Number (sales -16% YoY), and ProFrac (rev -11% YoY) reported sharp declines due to market softness and impairments. Capital allocation trends favor shareholders, with notable buybacks (Ibotta +$100M to $400M total, KLA new $7B program, AVY $572M), dividend hikes (KLA +21% to $2.30, Build-A-Bear +4.5% to $0.23), and debt refinancings (Southwest $500M term loan, Kodiak $1B notes). Biotech and SPACs offer catalysts (Solid Biosciences positive Phase 1/2 data, FDA Phase 3 alignment Q1 2026; Gyre $300M Cullgen acquisition Q2 2026), but energy explorers like New ERA (rev +66% offset by $12.1M impairment) and Serve Robotics (rev +46% but gross loss $15.4M) highlight volatility. Portfolio-level trends show 8/15 high-materiality 10-Ks with revenue growth averaging +15% YoY but margin compression in 6/15 (-avg 200bps), insider pledges in CZFS (multiple execs), and 12+ proxy votes clustered April 2026. Implications: Favor financials for stability, monitor consumer for tariff impacts, position for biotech/SPAC closings H1 2026.

25 high priority 25 medium 50 total filings
· daily

Biotech Small-Cap Approvals — March 11, 2026

Two small-cap biotech firms, Aurobindo Pharma Ltd and Prinston Inc, received FDA ANDA approvals for generic Siponimod and Gabapentin on March 6, 2026, both under standard review with no special designations. These neutral events enable generics portfolio expansion amid typical pricing pressures, lacking blockbuster or exclusivity upside. No cross-cutting bullish trends; monitor for competitive generic erosion in unspecified indications.

2 total filings
· daily

Big Pharma Approvals — March 11, 2026

GlaxoSmithKline's FDA supplemental approval for Wellcovorin (leucovorin calcium) under Priority Review with Orphan Drug designation signals moderate bullish momentum via potential label expansion and 7-year exclusivity. Lacking specified indication limits immediate market sizing, tempering revenue impact versus new molecular entities. Investors should monitor for therapeutic details to assess orphan premium potential in Big Pharma.

1 total filings
· daily

New Drug Approvals (Original) — March 11, 2026

FDA approved two ANDA generic drugs on 2026-03-06: Siponimod (Aurobindo Pharma) and Gabapentin (Prinstin Inc), both under standard review with no special designations, yielding neutral investment signals. These approvals enable portfolio diversification for generics sponsors amid commoditized markets lacking blockbuster potential. Cross-cutting pattern shows steady, non-disruptive ANDA flow, with pricing pressures offsetting entry gains; no material sector divergences.

2 total filings
· daily

DHS Homeland Security Contracts — March 11, 2026

DHS awarded $1.34B in firm-fixed-price construction contracts on March 11, 2026, with $1.11B (83%) concentrated in two border barrier projects to Fisher Sand & Gravel ($596M, El Centro, CA) and Granite Construction ($512M, Laredo, TX), signaling accelerated border security spending under NAICS 236220. Remaining awards target Coast Guard pier recapitalization ($117M to Whiting-Turner) and ICE detention renovation ($113M obligated, $642M potential to KVG), all with zero outlays and future starts in 2026. Bullish across-the-board for construction firms, but monitor funding realization and cost overruns.

4 total filings
· daily

Federal Construction & Infrastructure Contracts — March 11, 2026

DHS awarded $1.22B in firm fixed price construction contracts on a single day, with 85% ($1.11B) concentrated in CBP border barrier projects signaling accelerated border security infrastructure spend. Bullish for NAICS 236220 contractors Fisher Sand & Gravel, Granite Construction, and Whiting-Turner, unlocking multi-year revenue streams despite $0 outlayed to date. Uniform execution risks from fixed pricing and funding delays require vigilance amid 2.5-4.3 year performance horizons.

3 total filings
· daily

Federal IT & Cybersecurity Contracts — March 11, 2026

General Dynamics Information Technology secured a $159.7M delivery order from USPTO for enterprise cloud support through 2026-09-30, providing multi-year revenue visibility for parent General Dynamics Corp in federal IT services (NAICS 541512). Subawards claim 35% ($55.7M) of value, capping net retention, while $12.9M in unobligated options offers upside. This single large award highlights sustained federal demand for Agile/DevOps cloud amid USPTO modernization.

1 total filings
· daily

New Federal Contractors — March 11, 2026

DHS drives 82% ($1.34B) of $1.63B total value across 4 firm-fixed price construction contracts for border barriers/walls ($1.11B), piers ($117M), and detention ($113M), signaling multi-year capex surge in homeland security infrastructure with bullish signals for non-small constructors. General Dynamics IT gains $160M cloud visibility; Stanford's $131M NASA extension neutral amid cost-no-fee structure. Key risks include universal $0 outlays (delays) and fixed-price overrun exposure; opportunities in options (e.g., KVG to $642M).

6 total filings
· daily

Significant Contract Modifications ($10M+) — March 11, 2026

DHS dominates with 5/6 contracts totaling $1.34B (83% of $1.63B aggregate), fueling a border security and infrastructure construction boom via firm-fixed-price awards to Fisher Sand ($596M), Granite ($512M), Whiting-Turner ($117M), and KVG ($113M potential $642M). Bullish signals prevail (5/6) for construction firms with multi-year revenue visibility starting 2026, offset by uniform $0 outlays signaling funding delays. Neutral Stanford NASA R&D ($131M) and bullish GD IT ($160M) provide diversification, but FFP structures amplify cost overrun risks amid inflation.

6 total filings
· daily

Contract Deobligations Alert — March 11, 2026

DHS dominates with $1.34B in new construction awards for border barriers, walls, piers, and detention facilities, signaling accelerated U.S. border security infrastructure spend and bullish outlook for non-small construction firms. Total $1.63B obligated across 6 contracts (5 bullish, 1 neutral), all with $0 outlayed, representing future revenue streams in construction (NAICS 236220) and IT services. Firm fixed price structures prevalent, exposing contractors to cost overrun risks amid long performance periods to 2030.

6 total filings
· daily

Contract Option Exercises — March 11, 2026

DHS drives 5/6 contracts totaling ~$1.3B in firm-fixed price construction awards for border barriers, walls, piers, and detention facilities, signaling renewed infrastructure push with full obligations but $0 outlayed across most, indicating future revenue ramps. Construction firms (NAICS 236220) capture 80%+ of value via full/open competition, bullish for sector amid 2-4 year performance periods. Divergence: Single IT/cloud ($160M) and neutral NASA R&D ($131M) awards provide multi-year visibility but lower materiality.

6 total filings
· daily

Mega Contracts Monitor ($100M+) — March 11, 2026

DHS dominates with $1.34B in mega contracts (82% of total value) focused on border barriers, walls, Coast Guard piers, and ICE detention facilities, signaling accelerated U.S. border/security infrastructure spend amid policy continuity. Construction firms (NAICS 236220) capture 85% of value via firm-fixed-price awards, offering multi-year revenue visibility despite execution risks. Diversification limited to IT/cloud ($160M Commerce) and space R&D ($131M NASA neutral), with 5/6 bullish signals underscoring sector tailwinds.

6 total filings
· daily

High-Value Federal Grants ($5M+) — March 11, 2026

DHS dominates with 4/6 contracts totaling ~$1.34B (82% of $1.63B aggregate), fueling bullish signals for border security construction via firm fixed price awards to non-small firms like Fisher Sand & Gravel ($596M) and Granite ($512M). Multi-year performance periods (up to 2030) signal sustained revenue but with $0 outlay across most, indicating delayed realizations. Neutral Stanford NASA award ($131M) provides R&D stability; overall, prioritize construction exposure amid DHS infrastructure surge.

6 total filings